ASCO-GI – another surprising TIGIT success?
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Merck KGaA’s oncology catalyst approaches
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
New phase 1 projects enter hot fields
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
Sana regains some of its shine
The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.
Cell cycle niche seeks clinical validation
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
